Headshot photo of Richard T. Maziarz, M.D.

Richard T. Maziarz, M.D.

  • Professor of Medicine, School of Medicine


Dr Maziarz has been involved in clinical investigation and translational research, for over three decades, beginning with research and clinical training at the Dana-Farber Cancer Institute and the Brigham & Women’s Hospital and continuing in 1991 when he moved to OHSU to develop a transplantation immunology program and served as the medical director of the adult OHSU stem cell transplant program since 1994.

His research involved the immunology of transplantation or its complications, particularly in studying the immunopathophysiology of GVHD. He has served as principal investigator or co-investigator on over 100 clinical trials including multiple initiatives sponsored by numerous national transplant organizations including SWOG, CIBMTR, ISCT, NMDP and BMT CTN. Within the BMT CTN, he serves on the Steering committee, chaired the Regimen Related Toxicity Committee, was a member of the GVHD Committee and served as the principal investigator for the BMT CTN on the first multicenter, stem cell transplant trial for patients with advanced chronic lymphocytic leukemia (BMT CTN 0804).

He also served on the writing committee for the first national multicenter, randomized trial between conventional and reduced intensity transplantation (BMT CTN 0901) and for transplantation for HIV associated malignancies. He currently serves as Chair of the Regimen Related Toxicity Strategic Planning Committee of the BMT CTN for the planned State of the Science Symposium, to define cell therapy and transplant clinical trials over the next 5 years.

A special interest has been the intersection of transplantation and health policy; he has served as consultant to the Oregon Health Resource Commission assessing indications for autologous transplantation and analyzing efficacy of reduced intensity allogeneic transplantation as a standard of care for adults with hematologic malignancies. He also has been an active member of the Health Policy working committee of the CIBMTR, served as a member of the ASBMT reimbursement committee and served as Chair of the NMDP financial working group for their system capacity initiative regarding transplantation expansion and most recently is Chair of the Health Economics SIG for ASTCT. At OHSU, he had maintained a laboratory focused on basic and preclinical models focused on how to reduce the risks for morbidity and mortality associated with graft versus host disease.

Most recently, his focus has been on the toxicity and efficacy of immune effector cell therapy. He has opened IEC multiple trials, assisted in the generation/ writing of new emerging trials utilizing CART and NK cells for a variety of disease indications and was the Chair of the Scientific Steering Committee for the Juliet trial that led to the approval of tisagenlecleucel for advanced diffuse large B cell lymphoma.

Education and training

    • M.D., 1979, Harvard Medical School
  • Residency

    • University Hospitals of Cleveland, 1981
  • Fellowship

    • Immunology, Dana-Farber Cancer Institute, 1985
  • Certifications

    • American Board of Internal Medicine (internal medicine), 1982

Memberships and associations:

  • American Society of Hematology


Elsevier pure profile


  • {{ pub.journalAssociation.journal.name.text[0].value }}